OA
DOVA

Omega Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Omega Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-40,000
Closed -$892K – 99
2017
Q2 		$892K Buy
+40,000
New +$842K 0.04% 76

Other funds holding DOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Omega Advisors's DOVA Position: Q3 2017 in Review

Omega Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2017, closing a stake of 40,000 shares — an estimated $892K sold.

Omega Advisors first reported a position in DOVA in Q2 2017 and held it in 1 quarter. The position peaked at $892K in Q2 2017. 39 funds tracked by Wall St. Rank hold DOVA as of Q3 2017.

  • Omega Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Omega Advisors sold 40,000 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2017, an estimated $892K.
  • Omega Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Omega Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $892K in Q2 2017.
  • 39 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2017.

Based on Omega Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.